Kvika banki hf.
9.3.2021 17:46:25 CET | Globenewswire | Press release
On 23 February 2021 Kvika banki hf. ("Kvika") disclosed that Kvika, TM hf. ("TM") and Lykill fjármögnun hf. ("Lykill") had signed a merger plan for the companies. On 26 February 2021 it was further disclosed that two out of four provisos in the merger agreement of the companies from 25 November 2020 had been satisfied. Remaining provisos being the approval of the Financial Supervisory Authority of the Central Bank of Iceland ("FME") for the merger and approval of the companies’ shareholders.
Today, 9 March 2021, FME notified Kvika, TM and Lykill that the Financial Supervision Committee had discussed the application for approval of the companies’ merger. It is the conclusion of the Committee that the merger will be approved provided that the merger process will be completed in accordance with provisions of the Act on Public Limited Companies.
Shareholders’ meetings will be held in each of Kvika, TM and Lykill on 30 March 2021, where the merger of the companies is on the agenda, cf. meeting notifications published on 8 March 2021.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
KAYTUS SYSTEMS PTE. LTD.29.9.2026 03:30:22 CEST | Press release
KAYTUS KR2166V3 Accelerates AIHPC Data Processing at Petabyte Scale
Evosep29.9.2026 03:00:00 CEST | Press release
Evosep and Mass Dynamics Join Forces to Standardize Proteomics Sample Preparation for Pharma
Oatly Group AB (publ)28.9.2026 22:05:00 CEST | Press release
Oatly to Report Third Quarter 2026 Financial Results on October 28, 2026
Teva Pharmaceutical Industries Ltd28.9.2026 22:00:00 CEST | Press release
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
Unlimit Group A/S28.9.2026 20:22:13 CEST | Pressemeddelelse
Unlimit Group A/S: Sikrer ny kapital og styrker balancen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
